DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2011/0052712 A1 Eaton Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2011/0052712 A1 Eaton Et Al US 2011 0052712A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0052712 A1 Eaton et al. (43) Pub. Date: Mar. 3, 2011 (54) SPRAYABLE POLYMERS ASADHESION Publication Classification BARRIERS (51) Int. Cl. A6II 3/765 (2006.01) (76) Inventors: Donald J. Eaton, Los Altos, CA A6IR 9/14 (2006.01) (US); Bin Huang, Pleasanton, CA A6IP4/00 (2006.01) (US); Michael A. Savitt, River (52) U.S. Cl. ......... 424/493; 424/497; 424/499: 424/501; Hills, WI (US) 424/78.31; 424/78.37; 514/60: 514/53 (57) ABSTRACT A formulation for generating an adhesion barrier that (21) Appl. No.: 12/705,436 includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable poly (22) Filed: Feb. 12, 2010 mer and at least one water Soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a sur Related U.S. Application Data face of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the (60) Provisional application No. 61/237,669, filed on Aug. Surface. The film acts as an adhesion barrier by reducing or 27, 2009. preventing adhesion of the Surface to other body tissue. Patent Application Publication Mar. 3, 2011 Sheet 1 of 10 US 2011/0052712 A1 F.G. 1B ***3. FIG. 2 Patent Application Publication Mar. 3, 2011 Sheet 2 of 10 US 2011/0052712 A1 Step 1 Biodegradable polymer or polymers is dissolved into an organic or inorganic Solvent. Step 2 Solution is sprayed and dried to produce particles of the biodegradable polymer. Step 3 Particles of biodegradable polymer are blended with particles of water Soluble polymer to produce a biodegradable and water Soluble particle mixture. FIG. 3 Step 1 Prepare two separate polymer Solutions: one Solution is a biodegradable polymer dissolved in a first Solvent and other Solution is a water Soluble polymer dissolved in a Second Solvent Step 2 Two Solutions are mixed to form an emulsion containing two liquid phases. Step 3 Spray dry emulsion to form particles FIG. 4 Patent Application Publication Mar. 3, 2011 Sheet 3 of 10 US 2011/0052712 A1 FIG. 5A Patent Application Publication Mar. 3, 2011 Sheet 4 of 10 US 2011/0052712 A1 FIG. 6A F.G. 6B Patent Application Publication Mar. 3, 2011 Sheet 5 of 10 US 2011/0052712 A1 8. FIG. 8 Patent Application Publication Mar. 3, 2011 Sheet 7 of 10 US 2011/0052712 A1 Patent Application Publication Mar. 3, 2011 Sheet 8 of 10 US 2011/0052712 A1 F.G. 13 Patent Application Publication Mar. 3, 2011 Sheet 9 of 10 US 2011/0052712 A1 F.G. 14 Patent Application Publication Mar. 3, 2011 Sheet 10 of 10 US 2011/0052712 A1 FIG. 16 US 2011/0052712 A1 Mar. 3, 2011 SPRAYABLE POLYMERS ASADHESION configurations of the human body, and often difficult to place BARRIERS in hard to reach areas within the Surgical field. 0007. Several liquid solutions have also been marketed as CROSS REFERENCE TO RELATED adhesion prevention systems. Adept(R), developed by Baxter, APPLICATION for example and Resolve(R), developed by Synthemed, are 0001. This application claims benefit of and incorporates liquids that can be introduced directly to the intraperitoneal by reference U.S. Patent Application No. 61/237,669 which cavity. Specifically, they are used as an instillate after the was filed on Aug. 27, 2009. surgery, and the entire site is washed with the solution. How ever, since these products are liquid, they do not remain at the FIELD OF THE INVENTION Surgical site for very long past their introduction into and 0002 This invention relates generally to adhesion barriers around the Surgical site. As mentioned earlier, it is highly and in particular to sprayable and biodegradable polymer desirable for the material to be present and provide the barrier adhesion barriers for prevention of post-operative Surgical function for a pre-determined time period, which could be adhesion formation. many weeks. 0008 Gel-based adhesion barriers have been developed to DESCRIPTION OF THE RELATED ART overcome the shortcomings discussed above. SprayGel(R) by 0003 Post-operative surgical adhesions are a normal part Confluent, for example, is a spray composed of two polymers of the Surgical healing processes. Many adhesions are that combine upon spraying to create a film on the Surgical desired, and are an integral and important part of the healing site. Confluent Surgical markets a similar product, whereby of the surgical field. However, adhesions can also result in two liquids are combined prior to application to the Surgical unwanted scar tissue between vital structures in the body and site. can result in significant post-operative Surgical problems or 0009. An additional short-coming of the products men morbidity. Such adhesions can significantly impact an indi tioned above is their early absorption within the surgical field. vidual's health, well-being and quality of life. The formation It is desirable to have the adhesion barrier absorb over time, of post-operative Surgical adhesions in the abdomen can lead after fibrin and collagen have been formed to prevent adhe to chronic pain, infertility, and small bowel obstruction sion. This generally takes between 30-60 days and could be (SBO). Adhesions after thoracic and cardiac Surgeries can lead to serious consequences during Subsequent re-operative longer in patients with impaired wound healing. The current cardiothoracic procedures. gel-based absorbable products are generally absorbed within 0004. The incidence of adhesions forming after surgical one week, and thus only prevent adhesions in the early phase procedures is 100%, with less than 5% of adhesions being of healing. Thus, some adhesion still occurs after the product caused by inflammation. Adhesions form after all types of has been fully absorbed. The adhesion barrier film Cardio Surgeries (abdominal, pelvic, cardiac, thoracic, spinal, plas wrap is present up to 60 days, but has the shortcomings of the tic, hand, and knee). In the USA, the cost of abdominal and film-based barrier discussed above. pelvic adhesions to the healthcare system in 1998 was esti 0010. Another shortcoming of the mentioned products is mated at S1.6 billion based on 5.6 million surgical procedures the effectiveness of the particles in forming a cohesive film deemed “at risk” for developing postoperative related surgi that can resist or prevent tissue growth or penetration through cal complications. these barriers. The use of overlapping biodegradable particles 0005 Post-operative adhesions are a common, expensive that are capable of forming an effective barrier has thus far problem for patients and the healthcare system. Various been ignored. approaches have been considered to reduce or eliminate post Surgical adhesions. Such approaches include minimizing 0011 Ke and Sun describe blends of poly(vinyl alcohol) trauma to the tissue and tissue exposure to foreign body, and with poly(L-lactide) which have a higher water absorption placing physical barriers between injured tissue. It has been than poly(L-lactide) alone. (Starch, Poly(lactic acid) and Poly Suggested that separating the raw to prevent tissue surfaces (vinyl alcohol) Blends, Journal of Polymers and the Environ from coming into contact with each other during the healing ment, Vol. 11, No. 1 (January 2003) They also show that process significantly minimizes adhesion formation. As the blends of starch/poly(vinyl alcohol)/poly(L-lactide) have healing process takes weeks to months, it will be ideal to keep improved compatibility and mechanical properties over a the Surfaces apart, at their natural locations, without coming starch/poly(L-lactide) blend. into contact with each other during the period of healing. 0012 Despite advances in the field, additional improve Physical barriers are helpful in this regard as long as they can ments are desirable. In particular, it would be advantageous to be biocompatible and preferably biodegradable. Addition provide an adhesion barrier that is deliverable as an aerosol or ally, any such barrier should be easy to use and fit in with by brushing. This will allow direct and exact application to commonly used Surgical procedures and protocols. the desired sites, with minimal or no application to areas 0006. In the case of physical barriers, one of the more where adhesion is desired. Such a product would have the traditional methods involves placing a thin polymer-based advantages of being easier to store than a liquid or gel, while film at the Surgical site, usually upon the completion of the having greater contact with the desired treatment site than a Surgery. Such a method is presently marketed by Genzyme liquid. It will be manufactured to provide prolonged barrier Biosurgery (SeprafilmR) and Cryolife (CardioWrap(R). protection. It may effectively use particles that are capable of Limitations of such a method, however, are that the film must overlapping while forming an effective barrier. It may also be cut to correspond to the desired site which adds time to contain therapeutic agents to allow for delivery over time to a Surgery, the membranes are uniform and cumbersome to specific area of the surgical field. Such an adhesion barrier work with, difficult to configure to the infinite geometric would be simultaneously easy to use, efficacious and cost US 2011/0052712 A1 Mar. 3, 2011 effective. At least some of these objectives will be met by the 0023 FIG. 5A depicts an overhead view of an adhesion inventions described hereinafter. barrier film over a selected area of surface region of tissue. 0024 FIG. 5B depicts a cross-sectional view of the film of SUMMARY OF THE INVENTION FIG.S.A.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • General Agreement on Tariffs Andtrade
    RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • WO 2014/066058 Al 1 May 2014 (01.05.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/066058 Al 1 May 2014 (01.05.2014) P O P C T (51) International Patent Classification: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, C07K 16/46 (2006.01) A61P 9/00 (2006.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, A61K 39/395 (2006.01) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (21) International Application Number: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, PCT/US2013/064369 ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 10 October 2013 (10.10.201 3) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, LV, 13/658,699 23 October 2012 (23. 10.2012) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: ABBOTT CARDIOVASCULAR SYSTEMS KM, ML, MR, NE, SN, TD, TG).
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2011) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Compositions, Methods and Devices for Generating Nanotubes on a Surface
    Michigan Technological University Digital Commons @ Michigan Tech Michigan Tech Patents Vice President for Research Office 6-28-2016 Compositions, methods and devices for generating nanotubes on a surface Craig Richard Freidrich Michigan Technological University, [email protected] Tolou Shokuhfar Michigan Technological University, [email protected] Follow this and additional works at: https://digitalcommons.mtu.edu/patents Recommended Citation Freidrich, Craig Richard and Shokuhfar, Tolou, "Compositions, methods and devices for generating nanotubes on a surface" (2016). Michigan Tech Patents. 131. https://digitalcommons.mtu.edu/patents/131 Follow this and additional works at: https://digitalcommons.mtu.edu/patents US009376759B2 (12) United States Patent (io) Patent No.: US 9,376,759 B2 Friedrich et al. (45) Date of Patent: Jun. 28, 2016 (54) COMPOSITIONS, METHODS AND DEVICES (58) Field of Classification Search FOR GENERATING NANOTUBES ON A None SURFACE See application file for complete search history. (71) Applicant: MICHIGAN TECHNOLOGICAL (56) References Cited UNIVERSITY, Houghton, MI (US) U.S. PATENT DOCUMENTS (72) Inventors: Craig Richard Friedrich, Houghton, 2004/0176828 Al 9/2004 O’Brien MI (US); Tolou Shokuhfar, Houghton, 2009/0014322 A l * 1/2009 Ramarajan et al............ 204/286.1 MI (US) 2009/0093881 Al * 4/2009 Bandyopadhyay ... A61L 27/306 623/16.11 (73) Assignee: Michigan Technological University, (Continued) Houghton, MI (US) FOREIGN PATENT DOCUMENTS ( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 WO 2004/085098 10/2004 U.S.C. 154(b) by 200 days. w o 2011/116085 1/2011 w o 2013/040208 3/2013 (21) Appl.No.: 13/798,287 OTHER PUBLICATIONS (22) Filed: Mar.
    [Show full text]